## Hans Nissbrandt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11101574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors. Journal of Neuroscience, 2012, 32, 4812-4820.	1.7	305
2	lâ€DOPAâ€induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. Journal of Neurochemistry, 2010, 112, 1465-1476.	2.1	230
3	Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain, 2014, 137, 1998-2014.	3.7	174
4	Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiology of Disease, 2011, 42, 327-340.	2.1	146
5	GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology, 2016, 65, 54-66.	1.3	100
6	Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Medical Genetics, 2010, 11, 36.	2.1	95
7	GABAB-Receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. Synapse, 1993, 15, 229-238.	0.6	94
8	Placebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual Dysphoric Disorder. Neuropsychopharmacology, 2007, 32, 153-161.	2.8	80
9	Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. Brain Research, 2003, 973, 81-91.	1.1	74
10	The Stomach-Derived Hormone Chrelin Increases Impulsive Behavior. Neuropsychopharmacology, 2016, 41, 1199-1209.	2.8	69
11	Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. , 2005, 133B, 88-92.		68
12	Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease – a multicenter study. BMC Medical Genetics, 2014, 15, 131.	2.1	67
13	Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight. Diabetes, 2017, 66, 1062-1073.	0.3	66
14	PITX3 polymorphism is associated with early onset Parkinson's disease. Neurobiology of Aging, 2010, 31, 114-117.	1.5	65
15	Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. Physiology and Behavior, 2014, 136, 135-144.	1.0	63
16	Effects of mCPP on the Extracellular Concentrations of Serotonin and Dopamine in Rat Brain. Neuropsychopharmacology, 1999, 20, 287-296.	2.8	62
17	Inhibition of firing rate and changes in the firing pattern of nigral dopamine neurons by γ-hydroxybutyric acid (GHBA) are specifically induced by activation of GABAB receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 611-619.	1.4	59
18	Pharmacologically induced cessation of burst activity in nigral dopamine neurons: Significance for the terminal dopamine efflux. Synapse, 1994, 17, 217-224.	0.6	58

HANS NISSBRANDT

#	Article	IF	CITATIONS
19	Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. European Journal of Neuroscience, 2006, 24, 617-624.	1.2	54
20	Influence of ghrelin on the central serotonergic signaling system in mice. Neuropharmacology, 2014, 79, 498-505.	2.0	53
21	Noisy Galvanic Vestibular Stimulation Promotes GABA Release in the Substantia Nigra and Improves Locomotion in Hemiparkinsonian Rats. PLoS ONE, 2012, 7, e29308.	1.1	51
22	?-Hydroxybutyric acid (GHBA) induces pacemaker activity and inhibition of substantia nigra dopamine neurons by activating GABAB-receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 348, 491-7.	1.4	48
23	Escitalopram Administered in the Luteal Phase Exerts a Marked and Dose-Dependent Effect in Premenstrual Dysphoric Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 195-202.	0.7	45
24	The influence of serotoninergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology, 1992, 346, 12-19.	1.4	37
25	3-Methoxytyramine Formation Following Monoamine Oxidase Inhibition Is a Poor Index of Dendritic Dopamine Release in the Substantia Nigra. Journal of Neurochemistry, 1997, 69, 1684-1692.	2.1	20
26	Inhibition of dopamine re-uptake: Significance for nigral dopamine neuron activity. , 1997, 25, 215-226.		20
27	Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors. Experimental Neurology, 2010, 221, 251-259.	2.0	9
28	Kinesin Light Chain 1 Gene Haplotypes in Three Conformational Diseases. NeuroMolecular Medicine, 2010, 12, 229-236.	1.8	8
29	Dopamine Release in Substantia Nigra: Release Mechanisms and Physiological Function in Motor Control. , 2005, , 85-99.		6